Condition
Drug-Induced Nephropathy
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Unknown2
Completed1
Withdrawn1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07072468Phase 2Recruiting
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
NCT06122311Not ApplicableCompletedPrimary
Drug Nephrotoxicity Amelioration by N-acetylcysteine
NCT05613361Phase 3Unknown
The Effect of Curcumin Against Colistin-induced Nephrotoxicity
NCT05851222Unknown
A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs (NeoAKI STOP)
NCT02882373Phase 2WithdrawnPrimary
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
Showing all 5 trials